AML Prognostic Panel Cytogenetics PCR: Comprehensive Genetic Analysis for Acute Myeloid Leukemia
Understanding the AML Prognostic Panel
The AML Prognostic Panel Cytogenetics PCR represents a cutting-edge diagnostic approach for patients with Acute Myeloid Leukemia (AML). This comprehensive genetic analysis combines traditional cytogenetic techniques with advanced polymerase chain reaction (PCR) technology to provide a complete picture of the genetic landscape driving leukemia progression. By examining specific chromosomal abnormalities and gene mutations, this panel delivers critical information that directly influences treatment strategies and predicts patient outcomes.
Why This Test Matters in AML Management
Acute Myeloid Leukemia is a heterogeneous disease with varying genetic profiles that significantly impact treatment response and survival rates. The AML Prognostic Panel addresses this complexity by simultaneously analyzing multiple genetic markers that have proven clinical significance. This integrated approach allows hematologists and oncologists to move beyond one-size-fits-all treatment protocols and instead develop personalized therapeutic strategies based on individual genetic characteristics.
What the Test Measures and Detects
The AML Prognostic Panel Cytogenetics PCR provides comprehensive analysis of six critical genetic markers:
- AML/ETO Translocation: Detects the t(8;21) chromosomal translocation associated with favorable prognosis in certain AML subtypes
- INV16 Rearrangement: Identifies inversion of chromosome 16, commonly seen in acute myelomonocytic leukemia with eosinophilia
- PML/RARA Fusion: Screens for the t(15;17) translocation characteristic of acute promyelocytic leukemia (APL)
- FLT3 Mutations: Analyzes both internal tandem duplications (ITD) and tyrosine kinase domain (TKD) mutations associated with poor prognosis
- NPM1 Mutations: Detects nucleophosmin gene mutations that often indicate favorable outcomes when FLT3-ITD is absent
- CEBPA Mutations: Identifies CCAAT/enhancer-binding protein alpha gene mutations associated with intermediate-risk AML
Who Should Consider This Test
Clinical Indications and Symptoms
This comprehensive genetic panel is recommended for individuals who:
- Have been newly diagnosed with Acute Myeloid Leukemia
- Present with unexplained fatigue, weakness, or pallor
- Experience recurrent infections or unexplained fevers
- Show easy bruising, petechiae, or abnormal bleeding
- Have bone pain or joint discomfort without clear cause
- Display unexplained weight loss or night sweats
- Require risk stratification before initiating chemotherapy
- Need monitoring of minimal residual disease during treatment
Benefits of Taking the AML Prognostic Panel
Undergoing the AML Prognostic Panel Cytogenetics PCR offers numerous advantages for both patients and healthcare providers:
- Personalized Treatment Planning: Enables selection of targeted therapies based on specific genetic abnormalities
- Accurate Risk Stratification: Provides precise prognostic information to guide intensity of treatment
- Early Detection of High-Risk Features: Identifies genetic markers associated with poor outcomes for aggressive intervention
- Monitoring Treatment Response: Allows tracking of genetic markers during and after therapy
- Informed Decision Making: Empowers patients and physicians with comprehensive genetic information
- Improved Survival Outcomes: Facilitates evidence-based treatment selection that can enhance long-term survival
Understanding Your Test Results
Interpreting Genetic Findings
Your AML Prognostic Panel results will provide detailed information about the genetic characteristics of your leukemia. Results are typically categorized into favorable, intermediate, and adverse risk groups based on the specific mutations detected:
Favorable Genetic Markers
- AML/ETO translocation (t8;21)
- INV16 rearrangement
- PML/RARA fusion (with prompt differentiation therapy)
- NPM1 mutation without FLT3-ITD
- CEBPA double mutation
Adverse Genetic Markers
- FLT3-ITD mutations
- Complex karyotype abnormalities
- Monosomal karyotype
- TP53 mutations
Your oncologist will interpret these results in the context of your overall health, age, and other clinical factors to develop the most appropriate treatment plan. Regular follow-up testing may be recommended to monitor treatment response and detect any emerging resistance mutations.
Test Pricing and Availability
| Test Component | Price (USD) |
|---|---|
| Discount Price | $526 |
| Regular Price | $700 |
| Turnaround Time | 5-7 days |
| Sample Type | Bone marrow / Peripheral blood (Transport immediately) |
| Test Components | EDTA Vacutainer (3 ml) |
Nationwide Accessibility
We have diagnostic centers conveniently located across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our network of certified laboratories ensures consistent, high-quality testing standards regardless of location.
Take Control of Your Leukemia Treatment Today
Don’t leave your leukemia treatment to chance. The AML Prognostic Panel Cytogenetics PCR provides the genetic intelligence needed to make informed decisions about your care. With results available in just 5-7 days and comprehensive analysis of six critical genetic markers, this test represents a crucial step toward personalized leukemia management.
Ready to get started? Contact our genetic counseling team at +1(267) 388-9828 to schedule your test or discuss your results with our expert hematologists. Early genetic profiling can significantly impact treatment success and long-term outcomes in Acute Myeloid Leukemia.
Note: This test requires a doctor’s prescription and is not applicable for surgery and pregnancy cases or people planning to travel abroad. Our genetic counselors are available to help you understand the testing process and coordinate with your healthcare provider.
